Better assessments for early AMD

August 29, 2018

The European MACUSTAR consortium is conducting a multi-country clinical study on age-related macular degeneration (AMD) coordinated by the University of Bonn. The clinical study focuses on the intermediate stage of the disease, in which a person's vision under low-light and low-contrast conditions is impaired. Throughout Europe, a total of 20 study centers will recruit and follow-up with 750 patients. The study rationale and protocol has recently been published in the journal Opthalmologica.

Age-related macular degeneration (AMD) is associated with a progressive loss of photoreceptor cells at the point of sharpest vision. People older than 60 years are most affected, corresponding to around 2.5 million people in the European Union. The number of persons affected by AMD is expected to rise due to increasing life expectancy. Disease progress from an early stage to an intermediate stage is typically associated with low-light and low-contrast vision problems. Late stage AMD usually leads to irreversible central vision loss.

Currently, clinical tests available are good at diagnosing the loss of vision in late stage AMD. However, they are not sensitive to changes in vision in earlier stages of the disease, thus, hampering the testing of treatment methods to prevent or delay progression of early AMD stages. Therefore, MACUSTAR is developing novel tests to assess earlier stages of AMD.

20 Study Centers Examine 750 Patients in Europe

The core of the MACUSTAR project is a three-year observational study of 750 patients who have intermediate and other stages of AMD. They will be recruited by 20 participating clinical trial centers in seven European countries. Aim of the investigation is to find variables that provide reliable information on disease progression or stability, which could then be further developed into clinical tests.

The article published in the peer-reviewed journal Ophthalmologica summarizes the methods used to assess AMD and its impact on function and quality of life. For example, high-resolution imaging techniques will provide information on anatomical changes in the retina. Besides conventional visual function tests, vision under low-light conditions and contrast vision will be determined. Researchers will also capture the light sensitivity of the macula, the duration of dark adaptation, and reading speed and visual path navigation under low-light conditions. In addition, questionnaires will provide information on how visual impairment is perceived by the study participants. The MACUSTAR consortium aims to identify the best method or combination of methods that indicate if a novel therapeutic approach can stop AMD progression in the future.

The Consortium

Besides the University of Bonn and GRADE Reading Center Bonn, Moorfields Eye Hospital London (MBRC), University College London (UCL), City University of London (City), Fondation Voir et Entendre (FVE) Paris, Association for Innovation and Biomedical Research on Light and Image (AIBILI) Coimbra, Radbound University Medical Center (RUMC) Nijmegen, University of Sheffield and the European Clinical Research Infrastructures Network (ECRIN) Paris as well as the companies Bayer AG, Novartis Pharma AG, Carl Zeiss-Meditec and F. Hoffmann La-Roche are involved.

The MACUSTAR consortium received a €16 million grant from the Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) supported by the Horizon 2020 European Union Research and Innovation Framework Program and EFPIA.
-end-
More Information: http://www.macustar.eu or http://www.imi.europa.eu

Publication: Robert P. Finger, Steffen Schmitz-Valckenberg, Matthias Schmid, Gary S. Rubin, Hannah Dunbar, Adnan Tufail, David P. Crabb, Alison Binns, Clara I. Sánchez, Philippe Margaron, Guillaume Normand, Mary Durbin, Ulrich F. O. Luhmann, Parisa Zamiri, José Cunha-Vaz, Friedrich Asmus, Frank G. Holz: Development and clinical validation of functional, structural and patientreported endpoints in intermediate age-related macular degeneration, Ophthalmologica, DOI: 10.1159/000491402.

Contact:

Prof. Dr. med. Frank G. Holz

Prof. Dr. Dr. med. Robert Finger

University of Bonn, Dpt. of Ophthalmology

Phone 0228/287-15647

E-Mail: Frank.Holz@ukbonn.de, Robert.Finger@ukbonn.de

Web: http://www.augenklinik.uni-bonn.de

Acknowledgement: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116076. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA

Disclaimer: The contents of this press release reflect the view of the author. Neither the IMI nor the European Union or EFPIA are responsible for any use that may be made of the information contained therein.

University of Bonn

Related Disease Articles from Brightsurf:

CLCN6 identified as disease gene for a severe form of lysosomal neurodegenerative disease
A mutation in the CLCN6 gene is associated with a novel, particularly severe neurodegenerative disorder.

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

Potential link for Alzheimer's disease and common brain disease that mimics its symptoms
A new study by investigators from Brigham and Women's Hospital uncovered a group of closely related genes that may capture molecular links between Alzheimer's disease and Limbic-predominant Age-related TDP-43 Encephalopathy, or LATE, a recently recognized common brain disorder that can mimic Alzheimer's symptoms.

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects.

Tools used to study human disease reveal coral disease risk factors
In a study published in Scientific Reports, a team of international researchers led by University of Hawai'i (UH) at Mānoa postdoctoral fellow Jamie Caldwell used a statistical technique typically employed in human epidemiology to determine the ecological risk factors affecting the prevalence of two coral diseases--growth anomalies, abnormalities like coral tumors, and white syndromes, infectious diseases similar to flesh eating bacteria.

Disease-aggravating mutation found in a mouse model of neonatal mitochondrial disease
The new mitochondrial DNA (mtDNA) variant drastically speeds up the disease progression in a mouse model of GRACILE syndrome.

Human longevity largest study of its kind shows early detection of disease & disease risks
Human Longevity, Inc. (HLI) announced the publication of a ground-breaking study in the journal Proceedings of the National Academy of Sciences (PNAS).

30-year study identifies need of disease-modifying therapies for maple syrup urine disease
A new study analyzes 30 years of patient data and details the clinical course of 184 individuals with genetically diverse forms of Maple Syrup Urine Disease (MSUD), which is among the most volatile and dangerous inherited metabolic disorders.

Long-dormant disease becomes most dominant foliar disease in New York onion crops
Until recently, Stemphylium leaf blight has been considered a minor foliar disease as it has not done much damage in New York since the early 1990s.

Read More: Disease News and Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.